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CD200-positive cancer associated 
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Receptor mutation-positive lung 
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Cancer associated fibroblasts (CAFs) play important roles in the chemotherapeutic process, especially 
through influencing the resistance of tumor cells to molecular targeted therapy. Here we report the 
existence of a special subpopulation of patient-specific-CAFs that augment the sensitivity of EGFR 
gene mutation-positive lung cancer to the EGFR-tyrosine kinase inhibitor (EGFR-TKI), gefitinib. When 
cocultured with EGFR mutation positive lung cancer cells, these CAFs increased the apoptic effect of 
gefitinib on cancer cells, whereas, in the absence of gefitinib, they did not affect cancer cell viability. 
The assay using different single cell-derived clones demonstrated that the aforementioned sensitizing 
ability is clone-specific. Microarray analysis revealed that CD200 was expressed at much higher levels in 
this CAFs. Knocking down of CD200 expression deprived CAFs of their sensitizing potential, suggesting 
that CD200 is the functional molecule responsible for the effect. Immunohistochemical analysis of 
samples from patients receiving postoperative gefitinib treatment revealed that the individuals whose 
resected lung adenocarcinomas contained CD200-positive CAFs tended to have longer progression free 
survival of gefitinib when they recurred after surgery. These results suggest that CD200-positive CAFs 
can augment the sensitivity to EGFR-TKIs and may possess far reaching applications in the therapeutic 
use of EGFR-TKIs.
In patients with advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) 
mutations are reportedly a predictive factor for the effect of EGFR tyrosine kinase inhibitors (EGFR-TKIs)1–5. 
Compared to standard first line cytotoxic chemotherapy, EGFR-TKIs have been shown to prolong 
progression-free survival (PFS) in NSCLC patients with EGFR-activating mutations, such as exon 19 deletions 
and L858R point mutations1–7. However, 20% to 30% of patients with tumors harboring EGFR mutations exhibit 
intrinsic resistance to EGFR-TKIs. Moreover, patients who initially respond positively to EGFR-TKI treatment 
frequently develop resistance to these inhibitors8,9.
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Although the molecular mechanisms underlying acquired resistance have been extensively studied10–12, 
there are only a few reports that provide data regarding the factors that contribute to intrinsic resistance. Ng 
et al. presented data about the relationship between the BIM-deletion polymorphism and intrinsic resistance 
to EGFR-TKIs13. Engelman et al. and Yano et al. reported that the HGF-MET pathway induces resistance to 
gefitinib14,15. However, in over 50% of the cases where intrinsic resistance is observed, its causes are unknown16.
It is widely accepted that biological characteristics of stromal cells can be key regulators of resistance to anti-
cancer drugs17–20. Many investigators have reported that cancer-associated fibroblasts (CAFs) influence the sen-
sitivity to anticancer drugs via the secretion of extracellular matrix proteins, proteases, cytokines, and growth 
factors. Straussman et al. reported that CAF-secreted HGF induced intrinsic resistance of BRAF-mutant mel-
anoma to a RAF inhibitor17. Wang et al. reported that HGF from stromal fibroblasts confers intrinsic resist-
ance to EGFR-TKIs by activating MET, which restores the phosphorylation of downstream MAPK/extracellular 
signal-regulated kinases (MAPK-ERK 1/2) and activates the phosphoinositide 3-kinase (PI3K)/Akt signaling 
pathway in lung adenocarcinomas displaying EGFR mutations21,22. Recently, we reported that podoplanin-positive 
CAFs induce primary resistance to EGFR-TKIs in lung adenocarcinomas exhibiting EGFR mutations, with podo-
planin playing a functional role in this effect23. Therefore, the mechanisms underlying CAF-induced intrinsic 
resistance against gefitinib attract significant attention.
Even though CAFs reportedly decrease the antitumor effect of gefitinib, there have been clinical cases where 
an impressive response to gefitinib was observed24. In order to explain this contradiction, we hypothesized that 
certain types of CAFs might have the ability to augment sensitivity to gefitinib. Here, we report that CAFs isolated 
from a lung adenocarcinoma patient intensified the antitumor effect of gefitinib on EGFR mutation-positive lung 
adenocarcinoma cells.
Results
Antitumor effect of gefitinib on PC9 cells cocultured with CAFs. Generally, CAFs are believed to 
promote resistance of EGFR mutation-positive lung adenocarcinoma to EGFR-TKIs via soluble factors or direct 
contact, whereas the expression of these factors varies among CAFs derived from different tumors. We cocultured 
PC9-mRFP cells with CAFs isolated from five lung adenocarcinoma patients (patients IDs: 608, 621, 722, 1128 
and 1209) (Fig. 1A). Experiments with PC9-mRFP cells cocultured with CAF621, 1128 and 1209 gave results con-
sistent with those of previous reports; specifically, the numbers of PC9-mRFP cells in gefitinib-treated cocultures 
were significantly higher compared to gefitinib treated PC9-mRFP monocultures21,22. CAF722 did not change 
the number of viable PC9-mRFP cells after gefitinib treatment. Surprisingly, the number of viable PC9-mRFP 
cells observed after the administration of gefitinib on cocultures with CAF608 was significantly lower in compar-
ison with gefitinib-treated PC9-mRFP monocultures (7.2% vs 17.2%, P < 0.05) (Fig. 1B). This difference was not 
observed in the absence of gefitinib treatment (Supplemental Fig. 1A). These findings suggested that CAF 608 
cells augment the sensitivity of PC9 cells to gefitinib.
We repeated the assay with mRFP-labeled cells of a different cancer cell line, HCC827 which also harbors an 
EGFR mutation (exon 19 deletion). We obtained similar results (Fig. 1C), thus the sensitivity-enhancing effect of 
CAF608 cells is no specific to PC9 cells. A dose-effect curve revealed that the presence of CAF608 cells reduced 
the IC50 of gefitinib for reducing the number of PC9-mRFP cells from 11.7 nM to 8.7 nM (Fig. 1D). Our results 
suggest that the presence of CAF608 cells makes EGFR mutation-positive cell lines more sensitive to gefitinib. It 
should also be noted that CAF608 cells themselves are not sensitive to gefitinib, as administration of the drug to 
CAF608 monocultures did not affect the number of CAF608 cells (Supplemental Fig. 1B).
Our next step was to examine whether or not the increased sensitivity of PC9 cells to gefitinib was caused by 
soluble factors secreted by CAF608 cells. As seen in Supplemental Fig. 2A, the addition of CAF608 culture-derived 
supernatant to PC9-mRFP cultures not only failed to make cancer cells more sensitive to gefitinib, as was the 
case in the culture experiments, but actually caused a small increase in the number of viable PC9-mRFP cells 
compared to gefitinib-treated PC9-mRFP cultures to which no supernatant has been added (21.7% vs. 17.8%) 
(Supplemental Fig. 2B). In contrast, the effect of CAF621 culture-derived supernatant on the survival rate of 
PC9-mRFP after gefitinib treatment was similar to the one observed in the coculture experiments, i.e., a signifi-
cant increase in the number of viable PC9-mRFP cells was observed (35.7% vs. 17.8%, P < 0.05). RT-PCR assay 
revealed that CAF621 highly expressed HGF, a humoral factor known to enhance resistance against the antitumor 
effect of gefitinib (Supplemental Fig. 2C). Based on these results, it was expected that intensifying gefitinib sensi-
tivity by CAF608 might be caused by direct cell-cell contacts.
Measurement of p-Akt and p-ERK1/2. The PI3K/AKT pathway and the MAPK/ERK pathway are associ-
ated with the signaling pathways of several receptor tyrosine kinases, such as EGFR, and play a role in the intrinsic 
resistance to EGFR-TKIs22. We evaluated the p-Akt and p-ERK1/2 levels in PC-9 cells, alone or cocultured with 
CAF608 or CAF621 after gefitinib administration. In this coculture assay, we analyzed the phosphorylation sta-
tus of PC9-GFP cells after setting the FL1-positive threshold to an appropriate level (Supplemental Fig. 3A and 
Supplemental Fig. 4). Twenty-four hours after the addition of gefitinib, the levels of p-ERK1/2 in PC9-GFP cells 
cocultured with CAF621 cells were significantly higher than those of monocultured PC9-GFP cells (average of 
relative MFI: 0.62 vs. 0.14, P = 0.02). Cocultured PC9-GFP cells also displayed higher levels of p-AKT (0.69 vs. 
0.37), but the difference was not statistically significant. On the other hand, MFIs of p-ERK1/2 and p-Akt of 
PC9-GFP cells cocultured with CAF608 were 0.35 and 0.74 respectively and did not differ statistically signifi-
cantly compared to the respective values of PC9-GFP monocultures (Supplemental Fig. 3B and C). These findings 
suggest that the effect of CAF608 on gefitinib sensitivity is not mediated by either the MAPK or the PI3K pathway.
CAF608 does not affect the cell cycle status of PC9/Fucci2. The notable enhancement by CAF608 
cells of the gefitinib-induced decrease in the number of viable PC9 cells may be a result of increased cell cycle 
www.nature.com/scientificreports/
3Scientific RepoRts | 7:46662 | DOI: 10.1038/srep46662
arrest, increased cell death, or a combination of the two. In order to determine the cause, we added gefitinib 
to PC9/Fucci2 cells and counted PC9/Fucci2 that were in the G0/G1 or the S/G2/M phases of the cell cycle 
after 24 and 48 h (Supplemental Fig. 5 and Fig. 2A). The proportion of cells in G0/G1 cells (red fluorescence) in 
PC9/Fucci2 monocultures gradually increased after addition of gefitinib, with the average at 48 h was increased 
to 79.9%. The proportion of G0/G1 in PC9/Fucci2 cells in cocultures also increased with time after gefitinib 
treatment, with the average at 48 hours was 84.1%; there was no statistically significant difference in the G0/G1 
proportion between PC9/Fucci2 cells in monocultures and PC9/Fucci2 cells cocultured with CAF608 (Fig. 2B). 
In the absence of gefitinib, the proportion of G0/G1 PC9/Fucci2 cells was again similar in monocultures and 
cocultures, which is consistent with the results in Supplemental Fig. 1A.
Figure 1. Cocultures of PC9-mRFP cells and CAFs. (A) Design of an in vitro coculture model. The number 
of mRFP-positive PC9 cells were calculated 72 h after gefitinib administration. Images of PC9-mRFP cells (red 
cells) alone or in the presence of CAFs (non-labeled cells) are displayed at the left and right portion, respectively. 
(B) Relative numbers of PC9-mRFP cells cocultured with CAFs from five different patients, after treatment of 
the cultures with gefitinib. (C) Comparison of the percent of control of HCC827-mRFP cells when cultured 
alone or with CAF608 cells. (D) A dose-response study of the effect of gefitinib on the percent of control of PC9-
mRFP cells, cultured alone or with CAF608 cells.
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CAF608 increased the cell death rate of PC9 cells after gefitinib administration. We calculated 
the proportion of dead cells 24 and 48 h after gefitinib administration (Fig. 2C). As mentioned above, we have 
already confirmed that the number of CAF608 is not influenced by gefitinib treatment (Supplemental Fig. 1B). 
Thus, differences in the number of trypan blue-positive cells between gefitinib-treated cocultures of PC9 with 
CAF608 cells, and gefitinib-treated monocultures of PC9 cells, can be attributed to differences in the death rate 
of PC9 cells. Gefitinib treatment causes the proportion of trypan blue-positive cells to increase with time in both 
PC9-mRFP monocultures and cocultures with CAF608 cells, however the presence of CAF608 cells dramati-
cally increases the death rates. At 72 h, the proportion of dead cells in cocultures was almost twice compared to 
Figure 2. Cell cycle status analysis using PC9/Fucci2 cells, as well as evaluation of the proportion of 
PC9-mRFP dead cells, in monocultures or cocultures with CAF608. (A) Images of PC9/Fucci2 cells in 
monocultures and cocultures with CAF608. (B) The proportion of G0/G1 cells 24 and 48 h after gefitinib 
administration. (C) Images of dead PC9-mRFP cells from monocultures or cocultures with CAF608 after 
trypan blue staining (trypan blue-positive cells are indicated by arrows). (D) The proportion of trypan blue-
positive cells in PC9-mRFP monocultures or cocultures of PC9-mRFP and CAF608.
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monocultures (52.2% vs. 26.9%, P = 0.02). However, in the absence of gefitinib, the proportions of dead cells were 
similar in monocultures and cocultures (the averages at 72 h were 7.1% and 5.7%, respectively) (Fig. 2D). Based 
on these results, we conclude that CAF608 enhance the effect of gefitinib on PC9 cells mainly through increasing 
cell death rates, whereas, in the absence of gefitinib, CAF608 cells do not affect the viability of PC9 cells.
Specific CAF608 clone augments the antitumor effect of gefitinib. CAFs are generally viewed as a 
heterogeneous cell populations25. In order to support the hypothesis that the effect of CAF608 cells on gefitinib 
sensitivity is depended on specific CAF608 subpopulations, rather than being a synergistic or additive effect 
caused by interactions between different clones comprising CAF608, we performed an analysis using sin-
gle cell-derived CAF608 clones. First, we immortalized CAF608 (parent) by hTERT (Fig. 3A). Next, we tested 
whether the immortalized CAF608 (parent) were still able to increase the sensitivity of PC9-mRFP to gefitinib. 
This was confirmed by experiments comparing the number of viable PC9-mRFP after gefitinib treatment of 
PC9-mRFP monocultures or cocultures with CAF608 cells (6.3% vs. 18.9%, P < 0.05, “PC9” and “+ CAF608”). 
We next created the single cell-derived clones of the immortalized CAF608 cells. As mentioned in the Materials 
and Methods section, six CAF608 clones were finally established. Each of the six clones was tested with respect 
Figure 3. The relative numbers of PC9-mRFP cells in gefitinib-treated monocultures or cocultures with 
various CAF608 clones. (A) Fluorescence images of 6 clones derived from the CAF608 parent population. 
(B) The percent of control of viable PC9-mRFP cells cocultured with various CAF608 clones after gefitinib 
treatment.
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to its ability to enhance the sensitivity of PC9-mRFP cells to gefitinib. The number of viable PC9-mRFP cells 
cocultured with clone 4 after treatment with gefitinib was significantly lower compared with the number of viable 
PC9-mRFP cells in gefitinib-treated monocultures (9.3% vs. 18.9%, P < 0.05)(Fig. 3B). These results strongly 
suggest that a specific subpopulation of CAF608 cells is the one with the ability to enhance the sensitivity of PC9 
cells to gefitinib.
CD200 is highly expressed in CAF608 cells. To identify the key molecule, which enhances the antitumor 
effect of gefitinib, we performed a comprehensive transcriptome analysis using mRNAs from CAF608, CAF621, 
CAF608-clone 4 and CAF608-clone 6. The cluster analysis of these four groups is shown in Fig. 4A. There were 
1085 genes expressed in CAF608 at levels more than 4.0 times (the logarithm of 2 to base 2) higher compared to 
CAF621. Similarly, we identified 1530 genes that were expressed in CAF608-clone 4 more than 4.0 times higher 
compared to clone 6. The two lists had 112 common entries, which represent genes highly expressed in both 
CAF608 parent cells and CAF608-clone4 (Fig. 4B).
Experimental data presented in the first subsection chapter of “Results” suggested that direct con-
tact of CAF608 and PC9 cells is required for the former in increase the sensitivity of the latter to gefitinib 
(Supplemental Fig. 2). Thus, we used the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) Bioinformatics tool26,27 to filter the information provided by the Gene Ontology database on the 112 
genes whose annotations contained the terms “signal” and “cell membrane”. This led to a list of five genes: CD200, 
MDGA1, GRIN2A, ADGRL2 and NRCAM (Fig. 4C). We also chose to focus on CD200 and NRCAM, because 
these two are reportedly involved in heterotypic cell-cell communication. Our next step was to confirm the 
microarray data regarding the expression of these 2 genes through RT-PCR. The RT-PCR results regarding the 
expression levels of NRCAM were not consistent with those obtained by the microarray analysis. In contrast, the 
RT-PCR and microarray results of CD200 were in agreement (Fig. 4D). Therefore, we decided to focus on the 
CD200 protein as a candidate molecule.
CD200 expressed in CAF608 is the functional molecule that augments gefitinib sensitivity. We 
transfected CAF608 cells with shCD200, creating two CD200-knockdown CAF608 lines, called CAF608 
shCD200-1 and CAF608 shCD200-2 (Fig. 5A,B and Supplemental Fig. 6). Gefitinib was administered to cocul-
tures containing PC9-mRFP cells with either CAF608 shCD200-1, CAF608 shCD200-2 or control (CAF608 sh 
Luc) cells. After gefitinib treatment, the number of PC9-mRFP cells was significantly higher in the cocultures 
containing either of the two CD200-knockdown CAF608 cells than those containing the CAF608 sh Luc cells. 
(shCD200-1;19.4% and shCD200-2;18.6% vs. sh Luc;10.9%, P < 0.05, Fig. 5C). On the contrary, the number of 
CAF608 cells after gefitinib treatment was similar irrespective of the contained vectors (Fig. 5D), indicating that 
the observed changes in the viability between PC9-mRFP cells cocultured with CD200-knockdown CAF608 
cells and PC9-mRFP cells cocultured with control CAF608 sh Luc cells are not caused by CD200-related changes 
in the viability of the CAF608 cells themselves. We also performed experiments using CAF621 cells overex-
pressing CD200 (CAF621-CD200+, Fig. 5E). After gefitinib treatment, the number of viable PC9-RFP cells was 
significantly lower when the cancer cells were cocultured with CAF621-CD200+ compared to when they were 
cocultured with control CAF621 cells (19.4% vs. 28.1%, P < 0.05, Fig. 5F). Taking these results into account, we 
conclude that CD200 expressed by CAF608 cells is the functional molecule responsible for augmenting the sen-
sitivity of cancer cells to gefitinib.
Lung adenocarcinoma patients with CD200-positive CAFs tend to be associated with a better 
response to EGFR-TKIs. If CD200-positive CAFs augment the effect of gefitinib, one would expect the PFS 
of the patients possessing CD200-positive CAFs in the microenvironment of the tumor to be elongated after treat-
ment. To confirm this hypothesis, we examined a total of 90 patients displaying postoperative recurrence who 
were being treated with a gefitinib. We divided these patients in two groups based on the expression of CD200 by 
CAFs (Fig. 6A). Thirty of the patients had CD200-positive CAFs, which were also positive for α -SMA (a marker 
of CAFs). The proportions of EGFR Exon 19 deletion and L858R were almost equal in both the CD200-positive 
and the CD200-negative patient group (Supplemental Table 4). About 30 percent of patients in either of the two 
groups were being administered adjuvant chemotherapy. The majority of patients in both groups had a good 
performance status. The postoperative recurrence free survival was similar between CD200-positive and negative 
patients (p = 0.249, Fig. 6B). Conversely, the progression free survival after gefitinib treatment tended to be longer 
in patients with CD200-positive CAFs compared to patients with CD200-negative CAFs (p = 0.057, Fig. 6C).
Discussion
The emergence of resistance to EGFR-TKIs through a variety of mechanisms is the most serious problem in their 
clinical application. Methods for reversing the acquired resistance to EGFR-TKIs have been reported, such as 
Met kinase inhibitor, Metformin and Anti-HGF antibody15,28,29. However, researchers have largely overlooked the 
mechanisms underlying intrinsic resistance of cancer cells to EGFR-TKIs13,16. Furthermore, there are only some 
reports about the effect of CAFs on intrinsic resistance against EGFR-TKIs21,23, both of which report CAFs as a 
factor that makes cancer cells more resistant to these inhibitors. Therefore, our discovery of a subpopulation of 
CAFs that actually makes cancer cells more sensitive to gefitinib is a novel finding and reveals the diverse effects 
of CAFs on targeted cancer therapy. It is well known that CAFs play important roles in several aspects of tumor 
progression as well as in the chemotherapeutic process. However, CAFs derived from different patients exhibit 
different biological properties. Furthermore, even CAFs isolated from a single patient are a heterogeneous cell 
population in terms of functional potential25. The current study clearly demonstrates that CAFs consist of sub-
populations that can differ in their effects on cancer cell sensitivity to EGFR-TKIs. We could not observe the 
augmentation effect by fibroblasts which are derived from the normal alveolar lesion of lung in the same patient 
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as CAF608 (data not shown). Therefore our study demonstrates that the augmentation effect is the unique in 
CAF608. Our results suggest that CAFs should be divided into two categories with respect to their effect on can-
cer cell sensitivity; drug resistance-promoting and drug sensitivity-promoting phenotypes. CAF608 cells, which 
are studied in the current report, would obviously be classified into the second variety.
Through a process that included microarrays, bioinformatics analysis of results, and RT-PCR validation, we 
chose to focus on CD200, a membrane protein that is expressed in both the heterogeneous CAF608 population 
and its CAF608 clone 4 at levels much higher than in CAF621 cells. Experiments in which the CD200 gene 
was knocked down or overexpressed confirmed that CD200 is the protein that augments the antitumor effect of 
Figure 4. cDNA microarray analysis. (A) Heat map plot of CAF608, CAF621, CAF608-clone 4 and CAF608-
clone 6. (B) Venn diagram showing the number of common genes between the sets of genes whose expression 
in either the (heterogeneous) CAF608 population or the CAF608-clone 4 was at least four times higher than 
the expression in CAF621 cells or the CAF608-clone 6, respectively. (C) Venn diagram showing the 112 genes 
after enrichment for two gene ontology terms, “signal” and “cell membrane”. (D) Relative NRCAM and CD200 
mRNA levels of CAF608, CAF621, CAF608-clone 4 and CAF608-clone 6 cells as determined by RT-PCR assays.
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gefitinib. Moreover, the percentage of viable PC9 cells after gefitinib treatment in the presence of 1 μ M (24.6%) or 
10 μ M (24.8%) of recombinant human CD200 was statistically significantly lower (P < 0.05 for both concentra-
tions) compared to control cultures to which recombinant GFP had been added at a final concentration of 1 μ M 
(28.3%) or 10 μ M (32.5%) (Supplemental Fig. 7). Immunohistochemical analysis also demonstrated that lung 
cancer tissue containing CD200-positive CAFs tends to be more sensitive to gefitinib compared to tissue contain-
ing CD200-negative cell. CD200, also known as OX2 membrane glycoprotein, is normally expressed in neurons, 
hair follicle epithelial cells, lymphocytes and mesenchymal stem cells30. The interaction of CD200 with its receptor 
(CD200R1), which is expressed in macrophages, lymphocytes and monocytes triggers an immunosuppressive 
Figure 5. CD200 knockdown and overexpression assays. (A) Relative CD200 mRNA levels of CAF608 
cultures transfected with either control vector (sh Luc), sh CD200-1 or -2. (B) CD200 protein levels of CAF608, 
CAF608 sh Luc, sh CD200-1 and -2 cells. (C) The percent of control of viable PC9-mRFP cells after gefitinib 
treatment of cocultures consisting of PC9-mRFP and CAF608 sh Luc, CAF608 sh CD200 -1 or CAF608 
sh CD200-2 cells. (D) Numbers of CAF608 cells transfected with sh Luc, sh CD200-1 or -2 after gefitinib 
administration. (E) Infection efficacy of lentiviruses as determined by FACS analysis (X axis: FL-4H, Y axis: 
FSC-H). (F) The percent of control of viable PC9-mRFP cells observed after gefitinib treatment of PC9-mRFP 
cultured alone or cocultured with either CAF621-Control or CAF621-CD200+(overexpressing of CD200) cells.
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response that inhibits macrophage activity31. However, we did not detect CD200R expression in PC9 cells (data 
not shown). This suggests that CD200 exerts by interacting with a yet unknown receptor of cancer cells, whose 
activation triggers a pro-apoptotic signal cascade only upon EGFR-TKI treatment, through a pathway distinct 
from PI3K-Akt and/or ERK signaling. Alternatively, CD200 may induce a conformational change in other asso-
ciated molecules, resulting in pro-apoptotic signal transduction in tumor cells.
EGFR mutation-positive cell lines cocultured with CAF608 without gefitinib did not display changes in the 
number of dead cells, whereas the presence of gefitinib allows CAF608 cells to act as gefitinib sensitizers. These 
results support the introduction of a new treatment strategy against EGFR mutation positive NSCLC. Treatment 
with a combination of gefitinib and a cancer cell gefitinib sensitizer tailored according to how CAF608 exert 
this role may provide a better therapeutic result compared to administrations of gefitinib alone. Ramirez et al. 
revealed the presence of “drug-tolerant cancer persister cells” which are small subpopulations of cancer cells 
that evade strong selective drug pressure. They demonstrated the diversity of drug resistance mechanism arising 
from these cells by using an erlotinib-resistant cell line32. After a period of negligible growth, a small fraction of 
persister cells gain the ability to expand. Thus, cancer cell survivors such as drug-tolerant cancer persister cells 
Figure 6. The clinical impact of CD200-positive CAFs in lung adenocarcinoma patients treated with 
gefitinib. (A) Immunohistochemical findings of α -SMA-positive/CD200-positive and α -SMA-positive/CD200-
negative CAFs. (B) Recurrence free survival of EGFR mutation-positive lung adenocarcinoma patients with 
CD200-positive or CD200-negative CAFs. (C) Progression free survival of gefitinib-treated EGFR mutation-
positive lung adenocarcinoma patients with CD200-positive or CD200-negative CAFs.
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are considered one of the causes of acquired resistance. Targeting the survival and expansion of drug-tolerant 
cancer persister cells could be a powerful strategy for decreasing the chance of subsequent acquisition of genetic 
alterations. As CD200 maximizes the effect of gefitinib, it could reduce the number of drug-tolerant cancer per-
sister cells. It would be interesting to examine the possibility whether CAF608-iuduced sensitivity is also found in 
another TKI or another driver oncogene mutation positive lung cancer cell lines. We consider CD200-mediated 
CAF-cancer cell crosstalk to be a promising candidate for the development of novel treatment strategies against 
acquired resistance.
Materials and Methods
Clinical samples. All specimens were collected after obtaining written comprehensive informed consent 
from the patients. The study was conducted with the approval of the Institutional Review Boards of the National 
Cancer Center. IRB approval number of this study is 2014-070. All methods were carried out in accordance with 
the approved guidelines.
Cell culture and reagents. The EGFR mutant human lung adenocarcinoma cell lines PC-9 (del E746_
A750) and HCC-827 (del E746_A750) were purchased from the European Collection of Cell Culture and the 
American Type Culture Collection. The PC-9 and HCC827 cell lines were maintained in RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine serum (FBS; Sigma, St. Louis, MO), 1% glutamine, and antibiotics 
(1% penicillin and streptomycin; Sigma). The cultures were incubated at 37 °C in an atmosphere containing 5% 
CO2. Gefitinib was obtained from Tocris Bioscience (Ellisville, MO).
CAFs were prepared from human lung cancer tissues as previously reported33,34. The characteristics of the 
adenocarcinoma cases from which primary CAFs were obtained are shown in Supplemental Table 1.
Evaluation of the antitumor effect of gefitinib. PC9 (4.0 × 105 cells) or HCC827 (4.0 × 105 cells), labe-
led with monomeric red fluorescent protein (mRFP), were cocultured with an equal number of CAFs in 10 cm 
dishes as described previously23. Gefitinib (0.3 μ M, final concentration) or DMSO was added the next day. After 
72 h, we counted the PC9-mRFP or HCC827-mRFP cells using C-Chip disposable hemocytometers (Digital Bio, 
Seoul, South Korea) with an BZ-9000 inverted-type fluorescence microscope (Keyence, Japan) (Fig. 1A). The 
effect of gefitinib is evaluated by dividing the number of labeled cells after treatment with the inhibitor, with the 
number of cells in the control cultures (which were treated with DMSO), according to formula.
= −
− ×
Percent of control (%) ([the number of PC9 mRFP cells with gefitinib]
/ [the number of PC9 mRFP cells with DMSO]) 100
For practical reasons, henceforth this value is referred to as “percent of control” instead of “number of cells after 
treatment with the inhibitor expressed as a percentage of the number of cells observed after treatment with DMSO”.
Collection of condition medium. PC9-mRFP, CAF608 or CAF621 cells were seeded in 10 cm dishes 
(1.0 × 106 cells/dish) and incubated for 24 h. The supernatants of the CAF608 and CAF621 cultures were col-
lected, filtered using Steri-flip filter units (Merck Millipore, Billerica, MA, USA) and added to PC9-mRFP cells.
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Cells were washed with 
PBS and suspended in 1 ml of TRIzol (Invitrogen), then stored at − 80 °C. Total RNA was purified from thawed 
samples using standard techniques, and cDNA was synthesized using the PrimeScript RT reagent Kit (TaKaRa), 
according to the manufacturer’s instructions. RT-PCR was performed in a Smart Cycler System (TaKaRa) using 
SYBR Premix Ex Taq (TaKaRa) and Real time PCR Primers.
Informations of primers used were shown in Supplemental Table 2.
Measurement of p-Akt and p-ERK1/2. Measurement of phosphorylated-Akt and ERK1/2 of PC9 cells 
was performed as previously reported23. Briefly, PC9 labeled with Green Fluorescent Protein (GFP) and CAFs 
were plated in 10 cm dishes one day before gefitinib treatment. Twenty-four hours after the addition of gefitinib, 
cells were fixed with the addition of BD Phosflow Fix Buffer (BD Biosciences, Great Lakes, NJ, USA). After 15 min 
incubation at room temperature (RT), cells were permeabilized in ice-cold BD Perm Buffer III (prechilled at 
− 20 °C) for 30 minutes. The samples were washed with BD statin buffer and stained for 1 h with conjugated anti-
bodies recognizing p-Akt (Ser473) (Alexa Fluor® 647; Cell Signaling Technology), p-ERK1/2 (Thr202/Tyr204) 
(Alexa Fluor® 647; Cell Signaling Technology), as well as an IgG isotype control (BD Biosciences). We selected a 
region with GFP-positive cells as cancer cells for analysis. The relative mean fluorescence intensity (MFI) of p-Akt 
and p-ERK was defined as the MFI of each group divided by the MFI of PC9 cells without gefitinib treatment.
Generation of PC9/Fucci2 cells. The cell cycle was visualized using the Fucci2 system35. Lentiviruses were 
produced using 293T cells transfected with PCAG-HIV, pCMV-VSV-G-RSV-Rev (RIKEN BioResource Center, 
Tsukuba, Japan), and Fucci vectors (kindly provided by Dr. A. Miyawaki of the RIKEN Center). Transfection was 
achieved using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s 
instructions. Vector-containing medium was filtered through a 0.45 μ m filter, and 8 μ g/mL of polybrene (Santa 
Cruz Biotechnology, Dallas, TX, USA) was added to increase the efficiency of transduction. First, we transfected 
mCherry-hCdt1(30/120)/pCSII-EF-MCS into PC9 cells. The mCherry-positive cells were selected through FACS 
(FACSAria, BD Biosciences) and then transduced with Venus-hGeminin(1/110)/pCSII-EF-MCS. Venus-positive 
cells were sorted and named PC9/Fucci2. Thereafter, PC9/Fucci2 cells and samples of cells from each stage of their 
generation were fixed and stained with DRAQ5 (BioStatus, Shepshed, UK). DNA contents of each fraction were 
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analyzed by FACS (FACS caliber, BD Biosciences) and histograms were merged. The results confirmed that PC9/
Fucci2 cells display the same distribution as each PC9 fraction produced during their generation.
Evaluation of the proportion of G0/G1 cells using PC9/Fucci2 cells. PC9/Fucci2 cells (1.4 × 105 
cells/dish) were cocultured with an equal number of CAF608 cells in 6 cm dishes. At two time points (24 and 
48 h) after administration of 0.3 μ M gefitinib, we counted the mCherry positive cells and Venus positive cells. The 
proportion of G0/G1 positive PC-9 cells was calculated according to formula.
=
×
The proportion of G0/G1 cells (%)
[the number of mCherry positive cells]
/ [the number of mCherry positive cells and Venus positive cells]) 100
Evaluation of the number of PC9 dead cells by Trypan blue staining. PC9-mRFP cells were cocul-
tured with CAF608 in 6 cm dishes. Samples were collected (both floating and adherent cells) 48 and 72 h after 
administration of 0.3 μ M gefitinib, and stained with a 0.4% Trypan blue solution. The proportion of Trypan 
blue-positive cells was calculated with the following formula.
=
×
The proportion of Trypan blue positive cells(%)
([the number of Trypan blue positive cells]
/ [the number of Trypan blue positive cells and mCherry positive cells]) 100
Generation of CAF608 clones. Generation of CAF608 clones was performed as previously reported36. 
Briefly, single CAF608 cells expressing hTERT-Venus were sorted and seeded in 384-well plates. Fluorescence 
images were obtained every 12 h using the IncuCyte Live-Cell Imaging System (Essen Bioscience, Ann Arbor, 
MI, USA). After clones reached semi-confluence, they were replated on 96-well plates. We obtained a total of 6 
single-cell-derived clones.
Evaluation of the antitumor effect of gefitinib using PC9-mRFP cells cocultured with CAF608 
clones. PC9-mRFP cells (2.0 × 104 cells/well) were cocultured with an equal number of cells of one of each 
of the six CAF608 clones in 12-well plates (BD Falcon, BD Biosciences). PC9-mRFP cells were counted by flow 
cytometry as previously described23 at 72 h after gefitinib administration.
Microarray analysis. Total RNAs from cultured CAF608, CAF621, CAF608-clone 4 and CAF608-clone 6 
were isolated using RNeasy Mini kit (250) (QIAGEN). Cyanine-3 (Cy3) labeled cRNA was prepared from 0.1 ug 
Total RNA using the Low Input Quick Amp Labeling Kit (Agilent) according to the manufacturer’s instructions, 
followed by RNeasy column purification (QIAGEN, Valencia, CA). Dye incorporation and cRNA yield were 
checked with the NanoDrop ND-2000 Spectrophotometer. The 0.6 ug of Cy3-labelled cRNA was fragmented at 
60 °C for 30 minutes in a reaction volume of 25 ul containing 1× Agilent fragmentation buffer and 2× Agilent 
blocking agent following the manufacturer’s instructions. On completion of the fragmentation reaction, 25 ul of 
2× Agilent hybridization buffer was added to the fragmentation mixture and hybridized to Agilent SurePrint G3 
Human GE 8 × 60 K v2 Microarrays for 17 hours at 65 °C in a rotating Agilent hybridization oven. After hybrid-
ization, microarrays were washed 1 minute at room temperature with GE Wash Buffer 1 (Agilent) and 1 minute 
with 37 °C GE Wash buffer 2 (Agilent), then dried immediately. We scanned the slides immediately after washing 
on the Agilent SureScan Microarray Scanner (G2600D) using one color scan setting for 8 × 60 K array slides (Scan 
Area 61 × 21.6 mm, Scan resolution 3 um, Dye channel is set to Green PMT is set to 100%). The scanned images 
were analyzed with Feature Extraction Software 11.5.1.1(Agilent) using default parameters to obtain background 
subtracted and spatially detrended Processed Signal intensities (TaKaRa).
CD200 knockdown and overexpression studies. The oligonucleotides that were chemically synthesized 
for the CD200 short hairpin RNA (shRNA) experiments are displayed in Supplemental Table 3. To create entry 
clones, the top and bottom strands of the oligonucleotide were annealed and ligated into pENTR4-H1. Thereafter, 
a LR recombination reaction was performed between the entry clones and CS-RfA-EG using Gateway LR Clonase 
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Both pENTR4-H1 
and CS-RfA-EG were obtained from the RIKEN BioResource Center.
For the CD200 overexpression experiment, a lentivirus expression vector for human CD200 was generated by 
subcloning pUNO1-hCD200 (Invitrogen) into the CSII-CMV-RfA-IRES2-Venus vector.
The lentiviruses were produced using 293T cells previously prescribed37. Transfection was performed using 
the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions.
Western Blotting. Cells were lysed in whole-cell extraction buffer (20 mM HEPES-NaOH, 0.5% NP-40, 15% 
glycerol) containing a complete protease inhibitor cocktail (Roche, Basel, Switzerland). The proteins were sepa-
rated in a 12% SDS-polyacrylamide gel and transferred to an Immobilon-P PVDF membrane (Merck Millipore). 
Blots were incubated for 1 h at RT with a mouse monoclonal antibody recognizing human CD200 (Proteintech, 
Rosemont, IL, USA) or a mouse polyclonal antibody recognizing human β actin (Santa Cruz). After washing in 
TBS-T, the membranes were incubated for 1 h at RT with horseradish peroxidase-linked anti-mouse IgG (GE 
healthcare, Chicago, IL, USA). ECL Western Blotting Detection Reagents (GE Healthcare) were used to develop 
the high-performance chemiluminescence film (GE Healthcare).
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Patients included in this study. We selected 90 postoperative recurrent patients with lung adenocar-
cinoma harboring an EGFR-activating mutation that had been treated with gefitinib at our institution, in the 
period between January 2002 and December 2012. We identified mutations causing activation of EGFR in our 
patient pool (deletions in exon19, L858R point mutation, L861Q point mutation, and G719 missense point 
mutations) either through direct sequencing using a Cycleave PCR (SRL Diagnostics, NewDelhi, India), or the 
peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR-clamp method (LSI Medience, Tokyo, Japan), or a 
PCR-Invader Assay (Third Wave Technologies, WI, USA). We performed a clinical evaluation of PFS lasting from 
the initiation of gefitinib to the earliest identifiable sign of disease progression, as determined by evaluation data 
from CT or MRI imaging according to the RECIST (Response Evaluation Criteria In Solid Tumors) guidelines, or 
until occurrence of death from any cause.
Immunohistochemistry. Immunohistochemistry was performed using the BenchMark ULTRA system 
(Ventana Medical Systems, Tucson, Arizona, USA). Tissue sections were stained with antibody recognizing 
human CD200 (R&D systems, Minneapolis, MN, USA) or a monoclonal mouse antibody recognizing human 
smooth muscle actin (DAKO, Carpenteria, CA, USA). According to a previously reported definition38, we identi-
fied CAFs as spindle-shaped cells which were arranged in disarray fashion within the cancer stroma. A specimen 
was considered to be positive if at least 5% of the fibroblasts showed an unequivocal positive reaction for CD200.
Statistical analysis. We performed two-sided Mann-Whitney U tests and Kruskal-Wallis nonparamet-
ric tests to analyze our data. The recurrent free survival and progression free survival were estimated using the 
Kaplan-Meier method, and differences in the variables were calculated using the log-rank test. A P value lower 
than 0.05 was considered statistically significant, unless stated otherwise. All statistical analyses were performed 
with EZR (Saitama Medical Center of the Jichi Medical University, Shimotsuke, Japan), which is a graphical user 
interface for the R programming language that was developed by the R Foundation for Statistical Computing39. 
More precisely, EZR is a modified version of R-commander (Free Access), created by importing statistical func-
tions frequently used in biostatistics into the latter.
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